EP0876137A1 - Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus - Google Patents

Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus

Info

Publication number
EP0876137A1
EP0876137A1 EP97902167A EP97902167A EP0876137A1 EP 0876137 A1 EP0876137 A1 EP 0876137A1 EP 97902167 A EP97902167 A EP 97902167A EP 97902167 A EP97902167 A EP 97902167A EP 0876137 A1 EP0876137 A1 EP 0876137A1
Authority
EP
European Patent Office
Prior art keywords
groups
acid
unbranched
branched
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97902167A
Other languages
German (de)
English (en)
Inventor
Carola Jüstel
Manfred Klier
Jörg SCHREIBER
Florian Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP0876137A1 publication Critical patent/EP0876137A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/001—Preparations for care of the lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • A61Q9/02—Shaving preparations

Definitions

  • the present invention relates to the use of substances known per se as substances effective against bacteria, mycota and viruses.
  • the present invention relates to cosmetic and dermatological preparations containing such substances.
  • the healthy warm-blooded organism especially the healthy human skin, is populated with a large number of non-pathogenic microorganisms.
  • This so-called microflora of the skin is not only harmless, it is an important protection for the defense against opportunistic or pathogenic germs.
  • Bakte ⁇ en belong to the prokaryotic unicellular organisms. They can be roughly differentiated according to their shape (ball, cylinder, curved cylinder) and the structure of their tent wall (gram-positive, gram-negative). Finer subdivisions also take into account the physiology of the organisms. So there are aerobic, anaerobic and facultative anaerobic bacteria. Some individuals are of medical importance in their capacity as pathogenic germs, while others are completely harmless.
  • Antibiotics for example, which is not applicable to all antimicrobial substances, can be dated to the year 1941, although the first findings on penicillin were already found in 1929. Antibiotics in today's sense are not for all medical purposes, least of all non-cosmetic applications are suitable, since the warm-blooded organism, that is to say the sick patient, is often impaired in some way in its metabolic functions when used.
  • An object of the present invention was therefore to enrich the state of the art in this direction, in particular to provide substances which are effective against gram-positive and / or gram-negative bacteria without the use of the substances causing an unacceptable impairment of the Ge ⁇ health of the user would be connected.
  • Gram-negative germs are, for example, Escherichia coli, Pseudomonas species and Enterobacteriaceen, such as Citrobacter.
  • Gram-positive germs also play a role in cosmetics and dermatology.
  • bacterial secondary infections are of etiological importance in addition to other influences.
  • One of the main microorganisms associated with blemished skin is Propionibacterium acnes.
  • Impure skin and / or comedones affect the well-being of those affected, even in mild cases. Since practically every or every young person is affected by impure skin of any kind, there is a need for many people to remedy this condition.
  • a particular object of the present invention was therefore to find a substance or combination of substances which is effective against impure skin or Propionibacterium acnes.
  • the present invention relates to cosmetic deodorants.
  • Such formulations serve to eliminate body odor which arises when the odorless fresh sweat is decomposed by gram-positive microorganisms in particular.
  • the usual cosmetic deodorants are based on different active principles.
  • the sweat flow itself is not affected by this, ideally only the microbial decomposition of the sweat is temporarily stopped.
  • body odor can also be masked by fragrances, a method that least meets the aesthetic needs of the consumer, since the mixture of body odor and perfume smells rather unpleasant.
  • Deodorants should meet the following conditions:
  • Another object of the present invention was therefore to develop cosmetic deodorants which do not have the disadvantages of the prior art.
  • the deodorants should largely protect the microflora of the skin, but selectively reduce the number of microorganisms which are responsible for body odor.
  • a further task was to develop cosmetic deodorants which harmonize with the largest possible number of customary cosmetic auxiliaries and additives, in particular with the perfume constituents which are particularly important in formulations having a deodorant or antiperspirant effect.
  • a further object of the invention was to provide cosmetic deodorants which are effective over a longer period of time, on the order of at least half a day, without their action noticeably diminishing.
  • mycobionts include, for example, yeasts (Protoascomycetes), molds (Plectomycetes), powdery mildew (Pyrenomycetes), downy mildew (Phycomycetes) and the stand fungi (Basidiomycetes).
  • Fungi are not plant organisms, but like them, they have a cell wall, vacuoles filled with cell juice, and a microscopically visible plasma flow. They contain no photosynthetic pigments and are C-heterotrophic. They grow under aerobic conditions and gain energy through the oxidation of organic substances. However, some representatives, for example yeasts, are facultative anaerobes and are capable of generating energy through fermentation processes.
  • Dermatomycoses are diseases in which certain types of fungi, in particular dermatophytes, penetrate the skin and hair follicles.
  • the symptoms of dermatomycoses are, for example, blisters, exfoiiation, rhagades and erosion, mostly associated with itching or allergic eczema.
  • Dermatomycoses can essentially be divided into the following four groups: dermatophytias (e.g. epidermophytia, favus, microsporie, trichophytia), yeast mycoses (e.g.
  • Pathogenic and facultatively pathogenic germs include, for example, from the group of yeasts Candida species (for example Candida albicans) and those of the Pityro ⁇ sporum family.
  • a bet Pityrosporum ovale's involvement in the development of psoriasis is discussed by experts.
  • Dermatophytia almost exclusively affect skin, hair and nails. Hefemycoses can also affect mucous membranes and internal organs; system mycoses regularly extend to entire organ systems.
  • the areas of the body where clothing, jewelry or footwear can accumulate moisture and heat are particularly often affected.
  • the foot fungus is one of the best known and most widespread dermatomycoses. Fungal diseases of the finger and toenail areas (onychomycoses) are particularly unpleasant.
  • Superinfections of the type described above are, for example, secondary diseases which frequently occur in the full screen of AIDS. In itself - at least in low bacterial densities - harmless, but under certain circumstances also extremely pathogenic germs in this way monitor the healthy skin flora. With AIDS, however, other body organs are also affected by superinfections. Such superinfections are also observed in a large number of dermatological diseases, for example atopic eczema, neurodermatitis, acne, seborrheic dermatitis or psoriasis. Many medical and therapeutic measures, for example radio- or chemotherapy of tumor diseases, drug-induced immunosuppression or systemic antibiotic treatment, as well as external chemical or physical influences (e.g. environmental pollution, smog), promote the occurrence of superinfections of the external and internal organs, especially the skin and mucous membranes.
  • dermatological diseases for example atopic eczema, neurodermatitis, acne, seborrheic dermatitis or psori
  • topically administered antibiotics have the disadvantage that they not only free the skin flora from the secondary pathogen, but also severely impair the physiological skin flora and the natural healing process is slowed down again in this way.
  • the object of the present invention was to eliminate the disadvantages of the prior art and to make available substances and preparations containing such substances, the use of which can cure superinfections, the physiological skin flora not suffering any appreciable losses.
  • Protozoa are parasitic single-celled organisms with a clearly delineated cell nucleus that reproduce sexlessly (by double or quadruple division and budding), or sexually (Gameto, Gamonto and Autogamy). Food is taken in from the environment by permeation and by pinocytosis or phagocytosis. Most of the protozoa can, in addition to vegetative, usually mobile, forms of state (so-called trophozoites), under unfavorable circumstances, also form cysts as permanent forms.
  • protozoa are divided into four different groups: (a) Mastigophora (flagellates with flagella)
  • Protozoa living in parasitic areas in subtropical and tropical areas are often transmitted by stinging and sucking insects, but also by dirt and smear infections and by the food chain.
  • Trichomoniasis (caused by Trichomonas vaginalis), Lamblia dormancy (caused by Lamblia intestinalis), visceral as well as cutaneous and mucosal leishmaniasis (caused by Leishmania donovanii, L.tropica, L.brasiliensis, L- mexicana, L.diffusa or L.
  • trypanosmiasis caused by different types of Trypanosoma
  • amoebic dysentery and amebiasis caused by different types of Entamoeba, iodo-amoeba butschlii or Naegleria fowleri
  • coccidosis by Isospora belli
  • balantid dysentery caused by Balantidium coli
  • the way of life is either aprophytic or purely parasitic, possibly only as a periodic, temporary or stationary parasite.
  • the development of parasites is linked to one or more different host organisms, and humans can be intermediate hosts or end hosts.
  • helminths Medically and dermatologically significant parasites are, for example, the helminths, which in turn are subdivided into Trematodae, Cestodae and Nematodae.
  • the Helminthoses that impair human well-being include bilhistiasis (caused by Schistosoma species), tapeworm infestation from the intestine and other internal organs (caused by Taenia species and Echinococcus species, for example), Ascariasis (caused by Ascaris lumbricoides), enterobiasis ( caused by Enterobium vermicularis), paragonimiasis (caused by Paragonium species), filariasis (caused for example by Wucheria bancrofti) as well as other nematode infestations (for example caused by Trichuris trichura or Trichinella spiralis).
  • Fly and / or fly larvae infestation (caused, for example, by Glossina, Stomoxys, Tabanus, Chrysops, Lucilia, Chrysomya, Cochliamya, Wohlfartia, Cordylobia or Dermatobia species), mosquito and / or mosquito larvae infestation (caused for example by Aedes-Culex, Anopheses, Phlebotomus-Culicuides, Sumiiium or Haemagoges species), tick infestation (caused for example by Argas persicus and other Argas species, Ornithodorus erraticus and other Ornithodorus species.
  • Orobius- Rhiphocephalus- Dermacentor, Haemaphysalis, Amblyomma, Ixodes species), Porocephalose (caused by Porrocephaius species), flea infestations (caused by e.g.
  • Pulex irritans, Ctenocephaiides canis, Xenopsylla cheopsis, Nosophyllus fasciatus or Sarcopsylla pene- , Lice infestation (caused, for example, by Phthirius pubis, Pediculosus humanus or Pediculosus captits), bug infestation (caused, for example, by Cimex lectularius, Cimex hemipterus, Panstrongy lus megistus, Rhodnius prolixus, Triatoma dimidata, Triatoma infestans, Triatoma sordida or Triatoma brasiliensis) and mite infestation (caused, for example, by Demodex folliculorum and other Demodex species and by Dermamyskus species, Glyciphagus domesticus, Pyemotes species, Sar species coptes species or trombicula species).
  • the parsites living on or in the human organism can in turn be carriers of bacteria, mycota, protozoa and viruses which can have a lasting effect on the health and well-being of the host organism, for example humans.
  • a further object of the present invention was therefore to meet this need.
  • viruses are biological structures that require a host cell for biosynthesis.
  • Extracellular viruses also called “virions” consist of a single- or double-stranded nucleic acid sequence (DNA or RNA) and a protein coat (called a capsid), optionally an additional lipid-containing envelope (envelope).
  • DNA or RNA nucleic acid sequence
  • capsid protein coat
  • envelope envelope
  • the whole of nucleic acid and capsid is also The virus was classified classically according to clinical criteria, but nowadays mostly according to its structure, its morphology, but especially according to the nucleic acid sequence.
  • influenza viruses Orthomyxoviridae family
  • Lyssaviruses e.g. rabies, Rhabdovirus family
  • Enteroviruses e.g. Hepatitis-A, Picornaviridae family
  • Hepadnaviruses e.g. Hepatitis-B, Hepadnaviridae family
  • viruses-killing substances there are no virucides, that is to say viruses-killing substances in the actual sense, since viruses do not have their own metabolism. For this reason, it was also discussed whether viruses should be classified as living beings. In any case, pharmacological interventions without damage to the unaffected cells is difficult. Possible mechanisms of action in the fight against the viruses are primarily the disruption of their replication, for example by blocking the enzymes which are important for replication and which are present in the host line. The release of the viral nucleic acids into the host cell can also be prevented.
  • anti-viral or “active against viruses” 1 , “virucidal” or similar means the property of a substance, be it a single-cell or multicellular organism against harmful consequences of a virus infection, be it prophylactically or therapeutically to protect, regardless of what the actual mechanism of action of the substance in individual cases.
  • the prior art lacks substances which are active against viruses and which, moreover, do not damage the host organism, or do so to an acceptable degree.
  • (c6) unsubstituted cycloalkyl group with 3 to 7 ring atoms or one (c7) with one or more carboxyl groups and / or hydroxyl groups and / or oxo groups (keto groups) and / or branched and / or unbranched C- ⁇ 27-alkyl groups substituted cycloalkyl group with 3 to 7 ring atoms and wherein the ⁇ -hydroxycarboxylic acid or the ⁇ Hydroxycarboxylic acids, if appropriate in the form of their physiologically tolerable salts and / or ethyl esters and / or methyl esters, can remedy the disadvantages of the prior art.
  • active substance combinations as anti-bacterial, antimycotic, antiviral and / or active substances effective against protozoans and / or parasites is also according to the invention. It is particularly advantageous to use the active compound combinations according to the invention as active compounds which act against gram-positive bacteria.
  • Squalene (2,6,10, 15, 19,23-hexamethyl-2,6,10,14,18,22-tetracoshexaene, spinacene) is due to the structural formula
  • Sphingolipids and their use in pharmacy and cosmetics are also known per se.
  • the basic structure of the sphingolipids is sphingosine or phytosphingosine, which are characterized by the following structural formulas:
  • Sphingosine (phytosphingosine) Sphingolipids according to the invention are advantageously distinguished by the general basic structure
  • R- and R3 independently of one another represent saturated or unsaturated, branched or unbranched alkyl radicals of 1 to 28 carbon atoms
  • R2 is selected from the group: hydrogen atom, saturated or unsaturated, branched or unbranched alkyl radicals of 1 to 28 carbon atoms, sugar radicals, with organic radicals esterified or unesterified phosphate groups, with organic radicals esterified or unesterified sulfate groups and
  • Y represents either a hydrogen atom or a hydroxyl group or another hetero-functional radical.
  • the sphingolipids active according to the invention include the ceramides, cerebrosides, gangliosides, sphingophospholipids, of which in particular the sphingomyelins, sphingosulfatides and glycosphingosides and natural and synthetic analogs, examples of which are listed below:
  • Ri and R 3 represent alkyl radicals
  • R 2 represents a phosphate or organyl phosphate radical.
  • Sphingomyeline are organylphosphorylated sphingolipids
  • R2 is selected from the group of sugar residues, a distinction is usually made between whether monoglycosylceramides or di, tri or generally oligoglycosylceramides are present.
  • Monoglycosylceramides are commonly called cerebrosides:
  • Oligoglycosylceramides are mostly called gangliosides.
  • Preferred sphingolipids are ceramide I, II, III and IV, glucosylceramide, lactosylceramide and the gangliosides GM 1, 2 and 3.
  • ⁇ -hydroxycarboxylic acids are advantageously selected from the following classes of substances:
  • Group of C ⁇ o-18 ⁇ alkyl carboxylic acids can be selected, (c3) ⁇ -hydroxy sugar acids, aliphatic ⁇ -hydroxy fruit acids, (c4) unsubstituted aromatic ⁇ -hydroxy carboxylic acids (e.g. mandelic acid) or (c5) substituted aromatic ⁇ -hydroxy carboxylic acids.
  • ⁇ -hydroxyfatty acids falling under point (c2) are particularly advantageously selected from the group ⁇ -hydroxycarboxylic acids, according to the formula
  • n represents a number from 7 to 31.
  • ⁇ -hydroxycarboxylic acids which are C-
  • mixtures of such aliphatic ⁇ -hydroxycarboxylic acids in particular in the form of wool wax acid mixtures, in which the content of ⁇ -hydroxycarboxylic acids is 20-30% by weight, based on the total composition.
  • ⁇ -hydroxy sugar acids falling under point (c3) are selected particularly advantageously from the group of
  • Aidonic acids e.g. Gluconic acid, gaiactonic acid
  • Aldar acids e.g. Glucaric acid, galactaric acid (or fruit acid
  • Uronic acids e.g. Glucuronic acid, galacturonic acid
  • the aliphatic ⁇ -hydroxy fruit acids falling under point (c3) are particularly advantageously selected from the group of malic acid, lactic acid, citric acid, tartaric acid.
  • Malic acid (hydroxy succinic acid) is characterized by the following chemical structure: HOOC- CH 2 -CH- COOH I OH
  • Lactic acid (2-hydroxypropanoic acid) is characterized by the following chemical structure:
  • Citric acid (2-hydroxy-1, 2,3-propanetricarboxylic acid) is characterized by the following chemical structure:
  • citric acid is used for buffering cosmetic and / or dermatological preparations, but also as a synergist for antioxidants in skin and hair cosmetics.
  • Tartaric acid (dihydroxysuccinic acid) is characterized by the following chemical structure:
  • the active compound combinations according to the invention prevent the growth of gram-positive and gram-negative bacteria, mycobionts, protozoa, parasites and viruses.
  • the active compound combinations according to the invention act in a synergistic manner, that is to say superadditically with respect to the individual components.
  • the active compound combinations according to the invention are capable of preventing the growth of yeasts, in particular of the Pityrosporum species, namely Pityrosporum ovale.
  • the active compound combinations according to the invention prevent the formation of seborrheic symptoms, in particular dandruff. and to eliminate existing seborrheic phenomena, especially dandruff.
  • the active compound combinations according to the invention are also well suited for use as a deodorizing active ingredient in cosmetic deodorants and against impure skin, mild forms of acne or Propionibacterium acnes.
  • the active compound combinations according to the invention prevent the spoilage of organic substances, in particular cosmetic and dermatological preparations, from infestation with gram-positive and gram-negative bacteria, mycobionts, protozoa. Parasites and viruses can be prevented if they are added to these preparations.
  • the active compound combinations according to the invention are brought into contact with the area contaminated by mycobionts, if appropriate in a suitable cosmetic or dermatological carrier, and a process for protecting organic ones Products before infestation with mycobionts, characterized in that the active compound combinations according to the invention are added to these organic products in an effective amount.
  • a preferred embodiment of the present invention are therefore formulations to be used against dandruff, for example antidandruff shampoos.
  • the active compound combinations are preferably used in cosmetic or dermatological compositions with a content of 0.005-50.0% by weight, in particular 0.01-20.0% by weight, based on the total weight of the composition being preferred.
  • the compositions advantageously contain 0.02-10.0% by weight. particularly preferably 0.02-5.0% by weight of those according to the invention Active ingredient combinations, very particularly advantageously 0.5-3.0% by weight, based in each case on the total weight of the composition.
  • the active compound combinations according to the invention can be incorporated without difficulty into common cosmetic or dermatological formulations, advantageously in pump sprays, aerosol sprays, creams, ointments, tinctures, lotions, nail care products (e.g. nail polishes, nail polish remover, nail balsams) and the like.
  • nail care products e.g. nail polishes, nail polish remover, nail balsams
  • active substance combinations according to the invention with other active substances, for example with other antimicrobial, antimycotic or antiviral substances.
  • a pH range of 3.5 - 7.5 is advantageous. It is particularly favorable to choose the pH in a range from 4.0 to 6.5.
  • the cosmetic and / or dermatological formulations according to the invention can be composed as usual and can be used to treat the skin and / or hair in the sense of a dermatological treatment or a treatment in the sense of care cosmetics. But they can also be used in make-up products in decorative cosmetics.
  • the cosmetic and / or dermatological formulations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics and dermatics.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are advantageous. These advantageously additionally contain at least one UVA filter and / or at least one UVB filter and / or at least one inorganic pigment.
  • Cosmetic preparations according to the invention for protecting the skin from UV rays can be in various forms, such as are usually used for this type of preparation, for example.
  • they can be a solution, an emulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, or a multiple Emulsions, for example of the water-in-oil-in-water (W / O ⁇ / V) type, a gel, a hydrodispersion, a solid stick or an aerosol.
  • the cosmetic preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, antioxidants, perfumes, anti-foaming agents, dyes, pigments that have a coloring effect, thickening agents, surface-active substances, emulsifiers, softening substances, moisturizing and / or moisturizing substances.
  • Cosmetic auxiliaries e.g. Preservatives, bactericides, antioxidants, perfumes, anti-foaming agents, dyes, pigments that have a coloring effect, thickening agents, surface-active substances, emulsifiers, softening substances, moisturizing and / or moisturizing substances.
  • Fats, oils, waxes or other conventional components of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicon derivatives.
  • the cosmetic or dermatological preparation is a solution or lotion
  • the following can be used as solvents: water or aqueous solutions;
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil:
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethyienglykoimonomethyl or monoethyl ether and analog products.
  • Water can also be a component of alcoholic solvents.
  • antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocaninic acid) and their derivatives, peptides such as DL-camosin, D-carnosine, L- Camosin and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g.
  • thiols e.g. thioredoxin, glutathione , Cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl - and Glyceryl esters
  • salts dilauryl thiodipropionate. Distearyl thiodipropionate.
  • Thiodipropionic acid and its derivatives esters, ethers, peptides, lipids, nucleotides, nucleosides and salts
  • sulfoximine compounds e.g. buthioninsulfoximines, homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine
  • very low tolerable dosages e.g. pmol bis ⁇ mol / kg
  • further (metal) chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • ⁇ -hydroxy acids e.g.
  • citric acid lactic acid, apple acid
  • humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives
  • unsaturated fatty acids and their derivatives e.g. ⁇ -lininoic acid, linoleic acid, oleic acid
  • folic acid and their derivatives ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (e.g.
  • ascorbyipalmitate Mg - ascorbyl phosphate, ascorbyl acetate ), Tocopherols and derivatives (eg vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, Fe rulic acid and its derivatives, butylated hydroxytoluene, butylated hydroxyanisole, norydehydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g. ZnO, ZnS ⁇ 4) selenium and its derivatives (e.g.
  • stilbene methane eg stilbene oxide, trans-stilbene oxide
  • derivatives salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • Sofem vitamin A or vitamin A derivatives. or carotenes or their derivatives are the antioxidants, it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
  • Emulsions according to the invention are advantageous and contain e.g. the fats, oils, waxes and other fat bodies mentioned, as well as water and an emulsifier, as is usually used for such a type of formulation.
  • Gels according to the invention usually contain low C number alcohols. e.g. Ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickener which, in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, in the case of aqueous-alcoholic or alcoholic gels, preferably a polyacrylate is.
  • a thickener which, in the case of oily-alcoholic gels, preferably silicon dioxide or an aluminum silicate, in the case of aqueous-alcoholic or alcoholic gels, preferably a polyacrylate is.
  • Fixed pins according to the invention contain e.g. natural or synthetic waxes, fatty alcohols or fatty acid esters. Lip care sticks and desodorizing sticks (“deodorant sticks”) are preferred.
  • Suitable blowing agents for cosmetic or dermatological preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied blowing agents, e.g. Suitable hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with each other. Compressed air is also advantageous to use.
  • Suitable hydrocarbons propane, butane, isobutane
  • the preparations according to the invention can preferably also contain substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight. %, in particular 1 to 6% by weight, based on the total weight of the preparation, in order to To provide metallic preparations that protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
  • the UVB filters can be oil-soluble or water-soluble.
  • oil-soluble substances e.g. to call:
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-
  • Esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmaionic acid di (2-ethylOhexyl) ester;
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxy-benzophenone-5-sulfonic acid and their salts;
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidene-methyl) sulfonic acid and their salts.
  • UVB filters which can be used according to the invention, is of course not intended to be limiting.
  • U VA filters in preparations according to the invention, which are usually contained in cosmetic and / or dermatological preparations.
  • Such substances are preferably derivatives of Dibenzoylmethane, in particular 1- (4 , tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1, 3-dione.
  • Preparations containing these combinations are also the subject of the invention.
  • the same amounts of UVA filter substances that were mentioned for UVB filter substances can be used.
  • Cosmetic and / or dermatological preparations according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium. Zinc, iron, zirconium, silicon. Manganese, aluminum, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide. The amounts given for the above combinations can be used.
  • Cosmetic preparations for the care of the hair are, for example, shampooing agents, preparations which are used when rinsing the hair before or after the shampooing, before or after the permanent wave treatment, before or after the coloring or discoloration of the hair, in order to prepare the hair Blow-drying or inlaying the hair, preparations for coloring or decolouring, a styling and treatment lotion, a hair lacquer or permanent waving agents.
  • the cosmetic preparations contain active ingredients and auxiliaries of the kind normally used for this type of preparation for hair care and hair treatment.
  • Preservatives surface-active substances, substances for preventing foaming, emulsifiers, thickening agents, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments, the task of which is to dye the hair or the preparation itself, serve as auxiliary substances , Electrolytes, preparations for greasing hair.
  • Cosmetic preparations which are a shampoo or a washing, showering or bathing preparation preferably contain at least one anionic, non-ionic or amphoteric surface-active substance or mixtures thereof, Active ingredient combinations and auxiliaries according to the invention, as are usually used therefor.
  • Examples of surface active substances which can be used advantageously according to the invention are conventional soaps, e.g. Fatty acid salts of sodium, alkyl sulfates, alkyl ether sulfates, alkane and alkyl benzene sulfonates, sulfoacetates, sulfobetaines, sarcosinates, amidosulfobetaines, sulfosuccinates, sulfosuccinic acid half-esters, alkyl ether carboxylates, protein fatty acid condensates, alkyl betaines, fatty amide glycol amines, fatty amide glycol amines, amide glycol amine alcohols, and fatty acid amide glycol amines.
  • conventional soaps e.g. Fatty acid salts of sodium, alkyl sulfates, alkyl ether sulfates, alkane and alkyl benzene sulfonates,
  • the surface-active substance can be present in a concentration between 1% by weight and 50% by weight in the shampooing agent or in the washing, showering or bathing preparation.
  • This cosmetic or dermatological preparation can also be an aerosol with the auxiliaries normally used for it.
  • a cosmetic preparation in the form of a lotion that is not rinsed out, in particular a lotion for inlaying the hair, a lotion that is used for blow-drying the hair, a hairdressing and treatment lotion is generally an aqueous, alcoholic or is an aqueous-alcoholic solution and contains at least one cationic, anionic, non-ionic or amphoteric polymer or mixtures thereof, and combinations of active substances according to the invention.
  • the amount of the active compound combinations used according to the invention is e.g. between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.
  • Cosmetic and dermatological preparations for the treatment and care of the hair containing the active compound combinations according to the invention can be used as emulsions.
  • NEN which are of the non-ionic or anionic type.
  • non-ionic emulsions contain oils or fatty alcohols, which can be polyethoxylated or polypropoxyated, for example, or also mixtures of the two organic components.
  • These emulsions optionally contain cationic surface-active substances.
  • Anionic emulsions are preferably of the soap type and contain at least one ethoxylated or propoxylated organic compound according to the invention with an anionic or non-ionic character.
  • Cosmetic and dermatological preparations for the treatment and care of the hair can be in the form of gels which, in addition to the active compound combinations according to the invention and the solvents conventionally used therefor, also include organic thickeners, e.g. Gum arabic, xanthan gum, sodium aiginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g. Aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate, contain.
  • the thickener is in the gel e.g. in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • the amount of the active compound combinations according to the invention in an agent intended for the hair is preferably 0.01% by weight to 10% by weight, in particular 0.5% by weight to 5% by weight, based on the total weight of the preparations.
  • the liquid phase obtained by mixing the respective components together is filled into aerosol containers together with a propane-butane mixture (2: 7) in a ratio of 39:61.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Combinaisons de principes actifs comprenant (a) du squalène et (b) des sphingolipides, ainsi qu'éventuellement (c) une quantité efficace d'un ou plusieurs acides α-hydroxycarboxyliques de formule générale (I). L'invention concerne également leur utilisation en tant que principes actifs antibactériens, antimycosiques, antiviraux et/ou agissant contre les protozoaires et/ou les parasites.
EP97902167A 1996-01-22 1997-01-10 Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus Withdrawn EP0876137A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19602110A DE19602110A1 (de) 1996-01-22 1996-01-22 Gegen Bakterien, Parasiten, Protozoen, Mycota und Viren wirksame Zusammensetzungen auf der Basis von Squalen und Sphingolipiden
DE19602110 1996-01-22
PCT/EP1997/000079 WO1997026858A1 (fr) 1996-01-22 1997-01-10 Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus

Publications (1)

Publication Number Publication Date
EP0876137A1 true EP0876137A1 (fr) 1998-11-11

Family

ID=7783330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97902167A Withdrawn EP0876137A1 (fr) 1996-01-22 1997-01-10 Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus

Country Status (4)

Country Link
EP (1) EP0876137A1 (fr)
JP (1) JP2000505790A (fr)
DE (1) DE19602110A1 (fr)
WO (1) WO1997026858A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841795A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Sterole und Sterolderivate) und Mikrobiziden
DE19841794A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden
DE19841796A1 (de) * 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden
DE19844262B4 (de) 1998-09-26 2018-12-06 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an niedermolekularen Siliconen
FR2788689B1 (fr) * 1999-01-27 2002-06-07 Oreal Composition cosmetique comprenant au moins une cire et au moins un compose de type ceramide et procedes
JP3056730B1 (ja) * 1999-03-31 2000-06-26 株式会社バイオ技研 二形性真菌であるカンジダ属に対する形態転換制御活性機能剤
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
DE10330609A1 (de) 2003-07-07 2005-01-27 Beiersdorf Ag Fixierende Mehrfachgestaltung der Frisur erlaubende kosmetische Zubereitung
DE102006011314A1 (de) 2006-03-11 2007-10-18 Peter Dr. Engels Kosmetische Zubereitungen mit einem Zusatz aus der Baobab-Pflanze
DE102007003582A1 (de) 2007-01-24 2008-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Verwendung einer kosmetischen Zusammensetzung zur kosmetischen Behandlung der Haut
DE102009009004A1 (de) 2008-02-18 2009-09-17 Seaquist Perfect Dispensing Gmbh Abgabevorrichtung mit einem kosmetischen Fluid
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
DE102010002558A1 (de) 2009-11-20 2011-06-01 Symrise Ag Verwendung physiologischer Kühlwirkstoffe und Mittel enthaltend solche Wirkstoffe
WO2011061144A2 (fr) 2009-11-20 2011-05-26 Basf Se Utilisation de bêta-(1,3)-bêta-(1,4)-glucane ayant une masse moléculaire moyenne de 5 000 à 150 000 da pour augmentation de synthèse du collagène
JP5778908B2 (ja) * 2010-10-25 2015-09-16 株式会社ファンケル 水中油型乳化組成物
EP2758041B1 (fr) 2011-09-20 2021-01-13 Basf Se Modulateurs sous-moléculaires du récepteur de froid et de menthol trpm8 et leur utilisation
CN110573141A (zh) 2017-04-28 2019-12-13 西姆莱斯有限公司 欧蓍草鲜榨植物汁浓缩物、制造和应用
JP7231617B2 (ja) 2017-08-31 2023-03-01 ビーエーエスエフ ソシエタス・ヨーロピア 生理学的冷涼活性成分の使用、及びそのような活性成分を含む組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2099188C (fr) * 1992-07-24 2005-12-13 Paul A. Bowser Utilisation d'une composition cosmetique
JPH06247852A (ja) * 1993-02-22 1994-09-06 Sekisui Chem Co Ltd 炎症性皮膚疾患治療用外用剤
EP0716589A4 (fr) * 1993-07-23 1997-06-11 Morris Herstein Composition cosmetique stimulant le renouvellement de la peau, avec effet prolonge d'elimination de l'irritation
JPH07223934A (ja) * 1994-02-14 1995-08-22 Kanebo Ltd 皮膚化粧料
JPH08259420A (ja) * 1995-03-20 1996-10-08 Lion Corp 皮膚外用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9726858A1 *

Also Published As

Publication number Publication date
DE19602110A1 (de) 1997-07-24
JP2000505790A (ja) 2000-05-16
WO1997026858A1 (fr) 1997-07-31

Similar Documents

Publication Publication Date Title
WO1997026891A1 (fr) Sphingolipides actifs contre les bacteries, les parasites, les protozoaires, les champignons et les virus
DE19516705C2 (de) Gegen Bakterien, Mycota und Viren wirksame Substanzen
DE19543695A1 (de) Gegen Bakterien, Mycota und Viren wirksame Zusammensetzungen auf der Basis von alpha-Hydroxyalkansäuren und Squalen
EP0876137A1 (fr) Compositions a base de squalene et de sphingolipides, agissant contre les bacteries, les parasites, les protozoaires, les champignons et les virus
EP0869797A2 (fr) Utilisation des derives des glucides comme substances actives antimicrobiennes, antimycosiques et/ou antivirales
DE19602111A1 (de) Gegen Bakterien, Mycota, Parasiten, Protozoen und Viren wirksame Zusammensetzungen auf der Basis von Squalen, Sphingolipiden und Fettsäuren
EP0775478A1 (fr) Combinaisons d'agents actifs à base de glycérides partiels et d'acide acétique dialkylsubstitués
DE19634019A1 (de) Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
WO2011038797A1 (fr) Utilisation de magnolol ou d'honokiol en tant que principes actifs antibactériens, antimycosiques, antiparasitaires ou antiviraux
DE10025124B4 (de) Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
EP0821948A2 (fr) Combination d'agents actifs à base de glycérides partielles et d'acide acétique dialkylsubstitués ayant des propriétés antibactériennes, anti-mycotiques et anti-virales
EP2793820B1 (fr) Utilisation d'une association d'acide sorbique et d'un acide hydroxamique pour combattre les pellicules cappillaires.
DE19718777A1 (de) Verwendung von Estern aus Fettsäuren und Di- und Oligosacchariden gegen die Adhäsion von Mikroorganismen
DE19643585A1 (de) Antiadhäsive Sphingolipide
DE19634021A1 (de) Antiadhäsive Glycoglycerolipide
DE19826499A1 (de) Gegen Bakterien, Mycota, Viren, Parasiten und Protozoen wirksame Substanzen
DE19516702C2 (de) Gegen Bakterien, Mycota und Viren wirksame Substanzen
DE19742275A1 (de) Estern verzweigtkettiger Carbonsäuren und verzweigtkettiger Alkohole als antibakterielle, antimycotische, antiparasitäre oder antivirale Wirkstoffe
DE19643586A1 (de) Gegen Mikroorganismen, Viren, Parasiten und Protozoen wirksame Sterole und Sterolderivate
EP0838155A1 (fr) Stéroides et leurs dérivés possédant des propriétés anti-adhésives
EP0771561A2 (fr) Compositions antimycotiques, particulièrement actives contre les pellicules contenant des alcools aromatiques
DE10025122A1 (de) Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
EP2717837B1 (fr) Associations de principes actifs contenant la epsilon-poly-lysine (epsilon-poly-lysine) et un ou plusieurs esters, aldéhydes et/ou alcools aromatiques
WO1997035570A1 (fr) Utilisation d'acides monocarboxyliques insatures pour lutter contre des surinfections
EP2793815B1 (fr) Utilisation d'une préparation dermatologique comprenant une association de principes actifs d'un ou plusieurs alkyl ethers de glycerol et d'un ou plusieurs acides hydroxamiques physiologiquement sans danger

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980703

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

RTI1 Title (correction)

Free format text: COMPOSITIONS BASED ON SQUALENE AND SPHINGOLIPIDS AND EFFECTIVE AGAINST BACTERIA, PARASITES, PROTOZOA, FUNGI AND VIRUSES

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: COMPOSITIONS BASED ON SQUALENE AND SPHINGOLIPIDS AND EFFECTIVE AGAINST BACTERIA, PARASITES, PROTOZOA, FUNGI AND VIRUSES

17Q First examination report despatched

Effective date: 20010709

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010801